NVS 20-F DEF-14A Report Dec. 31, 2022 | Alphaminr
ALPHAMINR

NVS 20-F Report ended Dec. 31, 2022

Balance Sheet
Cash Flow
Income Statement
Debt
Name: NOVARTIS AG <br /> CIK: 1114448 <br /> Filing Type: 20-F/A <br /> Report Date: 2022-12-31 <br /> Download URL: https://www.sec.gov/Archives/edgar/data/1114448/000137036823000048/nvs-20221231.htm <br />
TABLE OF CONTENTS
Part IItem 1. Identity Of Directors, Senior Management and AdvisersItem 2. Offer Statistics and Expected TimetableItem 3. Key InformationItem 4. Information on The CompanyItem 4A. Unresolved Staff CommentsItem 5. Operating and Financial Review and ProspectsItem 6. Directors, Senior Management and EmployeesNote 27 To The Group S Audited Consolidated Financial StatementsItem 7. Major Shareholders and Related Party TransactionsItem 8. Financial InformationItem 9. The Offer and ListingItem 10. Additional InformationItem 11. Quantitative and Qualitative Disclosures About Market RiskItem 12. Description Of Securities Other Than Equity SecuritiesPart IIItem 13. Defaults, Dividend Arrearages and DelinquenciesItem 14. Material Modifications To The Rights Of Security Holders and Use Of ProceedsItem 15. Controls and ProceduresItem 16A. Audit Committee Financial ExpertItem 16B. Code Of EthicsItem 16C. Principal Accountant Fees and ServicesItem 16D. Exemptions From The Listing Standards For Audit CommitteesItem 16E. Purchases Of Equity Securities By The Issuer and Affiliated PurchasersItem 16F. Change in Registrant S Certifying AccountantItem 16G. Corporate GovernanceItem 16H. Mine Safety DisclosureItem 16I. Disclosure Regarding Foreign Jurisdictions That Prevent InspectionsPart IIIItem 17. Financial StatementsItem 18. Financial StatementsItem 19. ExhibitsNote 29 Contains A Maturity Table Of The Group S Future Contractual Interest Payments CommitmentsNote 28 Contains Additional Information on Contingent LiabilitiesNote 20 Contains Additional Information on These MattersNote 20 Contains Additional Information on Environmental Liabilities

Exhibits

Articles of Incorporation of Novartis AG, as amended March 2, 2021 (English translation) (incorporated by reference to Exhibit4.1 to Novartis AGs registration statement on FormS-8 (File No.333-258081) as filed with the SEC on July 22, 2021).Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG, effective January 1, 2021 (incorporated by reference to Exhibit 1.2 to Novartis AGs Annual Report on Form 20-F (File No. 001-15024) as filed with the SEC on January 26, 2021).Form of Second Amended and Restated Deposit Agreement among Novartis AG, JPMorgan Chase Bank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Receipts issued thereunder (incorporated by reference to Exhibit99.A to the Registration Statement on FormF-6 (File No.333-198623) as filed with the SEC on December 16, 2022).Form of American Depositary Receipt (incorporated by reference to Exhibit99.A to the Registration Statement on FormF-6 (File No.333-198623) as filed with the SEC on December 16, 2022).Description of Securities registered under Section 12 of the Exchange Act.Certification of Vasant Narasimhan, Chief Executive Officer of Novartis AG, pursuant to Section302 of the Sarbanes-Oxley Act of 2002.Certification of Harry Kirsch, Chief Financial Officer of Novartis AG, pursuant to Section302 of the Sarbanes-Oxley Act of 2002.Certification of Vasant Narasimhan, Chief Executive Officer of Novartis AG, pursuant to Section18 U.S.C. Section1350, as adopted pursuant to Section906 of the Sarbanes-Oxley Act of 2002.Certification of Harry Kirsch, Chief Financial Officer of Novartis AG, pursuant to Section18 U.S.C. Section1350, as adopted pursuant to Section906 of the Sarbanes-Oxley Act of 2002.Consent of KPMG AG.Consent of PricewaterhouseCoopers AG.